CA2916749C - Sulfated polygulonic acid polysaccharide or pharmaceutical salt thereof, preparation method therefor and use thereof - Google Patents

Sulfated polygulonic acid polysaccharide or pharmaceutical salt thereof, preparation method therefor and use thereof Download PDF

Info

Publication number
CA2916749C
CA2916749C CA2916749A CA2916749A CA2916749C CA 2916749 C CA2916749 C CA 2916749C CA 2916749 A CA2916749 A CA 2916749A CA 2916749 A CA2916749 A CA 2916749A CA 2916749 C CA2916749 C CA 2916749C
Authority
CA
Canada
Prior art keywords
inhibitors
acid sulfate
pharmaceutically acceptable
polygulonic acid
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2916749A
Other languages
English (en)
French (fr)
Other versions
CA2916749A1 (en
Inventor
Jian Ding
Jing AI
Yi Chen
Xun HUANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Publication of CA2916749A1 publication Critical patent/CA2916749A1/en
Application granted granted Critical
Publication of CA2916749C publication Critical patent/CA2916749C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA2916749A 2013-07-02 2014-07-02 Sulfated polygulonic acid polysaccharide or pharmaceutical salt thereof, preparation method therefor and use thereof Expired - Fee Related CA2916749C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310275323.7 2013-07-02
CN201310275323.7A CN104277130A (zh) 2013-07-02 2013-07-02 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途
PCT/CN2014/081472 WO2015000411A1 (zh) 2013-07-02 2014-07-02 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途

Publications (2)

Publication Number Publication Date
CA2916749A1 CA2916749A1 (en) 2015-01-08
CA2916749C true CA2916749C (en) 2021-03-09

Family

ID=52143111

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2916749A Expired - Fee Related CA2916749C (en) 2013-07-02 2014-07-02 Sulfated polygulonic acid polysaccharide or pharmaceutical salt thereof, preparation method therefor and use thereof

Country Status (19)

Country Link
US (1) US10058566B2 (enExample)
EP (1) EP3018147B1 (enExample)
JP (2) JP6757249B2 (enExample)
KR (1) KR102258569B1 (enExample)
CN (2) CN104277130A (enExample)
AU (1) AU2014286711B2 (enExample)
BR (1) BR112015032849B1 (enExample)
CA (1) CA2916749C (enExample)
DK (1) DK3018147T3 (enExample)
EA (1) EA028655B1 (enExample)
ES (1) ES2674976T3 (enExample)
HU (1) HUE038981T2 (enExample)
MX (1) MX373099B (enExample)
PL (1) PL3018147T3 (enExample)
PT (1) PT3018147T (enExample)
SG (1) SG11201510717SA (enExample)
TR (1) TR201809674T4 (enExample)
WO (1) WO2015000411A1 (enExample)
ZA (1) ZA201509353B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104277130A (zh) * 2013-07-02 2015-01-14 中国科学院上海药物研究所 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途
CN107904240A (zh) * 2017-12-04 2018-04-13 辽东学院 一种抗肝癌细胞转移的抑制剂组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228231A1 (de) 1982-07-28 1984-02-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München Arzneimittel, calciummischsalze von polymeren, anionischen carbonsaeuren und/oder schwefelsaeureestern, verfahren zu ihrer herstellung und ihre verwendung
JPH0625304A (ja) 1992-07-06 1994-02-01 Higeta Shoyu Co Ltd ガラクトサミン重合体硫酸化物及び該物質を 含有する抗ウイルス剤
CN1132209A (zh) 1995-03-27 1996-10-02 青岛海洋大学 一种新药多聚甘露糖醛酸硫酸盐
GB2317182B (en) 1996-09-11 2000-11-01 Johnson & Johnson Medical Sulfated polysaccharides and uses thereof in medical treatment
CN1473836A (zh) 2003-08-04 2004-02-11 中国海洋大学 还原端1位为羧基的古罗糖醛酸寡糖及其衍生物
CN1213071C (zh) * 2003-11-25 2005-08-03 中国海洋大学 一种古糖酯及其制备方法和应用
JP4897310B2 (ja) 2006-02-28 2012-03-14 理研食品株式会社 Ｌ−グルロン酸金属塩又はｄ−マンヌロン酸金属塩の製造方法
JP2008027767A (ja) 2006-07-21 2008-02-07 Aomori Prefecture 固体高分子電解質膜及び燃料電池
CN101691410B (zh) * 2009-09-18 2011-12-28 中国海洋大学 一种具有防治胰岛素抵抗作用的海洋寡糖铬配合物
RU2553348C2 (ru) 2010-03-10 2015-06-10 Айновобайолоджик, Инк. Продукт, содержащий глюкоманнан, ксантановую камедь и альгинат для лечения метаболических нарушений
CN102743409B (zh) 2012-06-18 2013-11-20 中国海洋大学 聚甘露糖醛酸丙酯硫酸盐在制备抗甲型h1n1流感病毒药物中的应用
CN104277130A (zh) * 2013-07-02 2015-01-14 中国科学院上海药物研究所 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途

Also Published As

Publication number Publication date
EA028655B1 (ru) 2017-12-29
AU2014286711A1 (en) 2016-02-04
EA201690123A1 (ru) 2016-07-29
MX2016000043A (es) 2016-05-31
CA2916749A1 (en) 2015-01-08
ES2674976T3 (es) 2018-07-05
CN104277130A (zh) 2015-01-14
CN105358582B (zh) 2018-09-21
MX373099B (es) 2020-03-31
JP6772318B2 (ja) 2020-10-21
JP2016523301A (ja) 2016-08-08
US10058566B2 (en) 2018-08-28
HUE038981T2 (hu) 2018-12-28
BR112015032849B1 (pt) 2021-09-14
EP3018147B1 (en) 2018-05-23
SG11201510717SA (en) 2016-01-28
KR20160029817A (ko) 2016-03-15
TR201809674T4 (tr) 2018-07-23
JP6757249B2 (ja) 2020-09-16
KR102258569B1 (ko) 2021-05-28
ZA201509353B (en) 2017-08-30
AU2014286711B2 (en) 2018-05-10
HK1220984A1 (zh) 2017-05-19
US20160367591A1 (en) 2016-12-22
JP2019090056A (ja) 2019-06-13
EP3018147A1 (en) 2016-05-11
PT3018147T (pt) 2018-07-17
WO2015000411A1 (zh) 2015-01-08
PL3018147T3 (pl) 2018-10-31
EP3018147A4 (en) 2017-04-05
DK3018147T3 (en) 2018-07-23
CN105358582A (zh) 2016-02-24
BR112015032849A2 (pt) 2020-05-12

Similar Documents

Publication Publication Date Title
Davydova et al. Cytokine-inducing and anti-inflammatory activity of chitosan and its low-molecular derivative
Wu et al. Structural analysis and anti-cancer activity of low-molecular-weight chondroitin sulfate from hybrid sturgeon cartilage
Wang et al. A polysaccharide from Inula japonica showing in vivo antitumor activity by interacting with TLR-4, PD-1, and VEGF
CN106832059A (zh) 一种具有肿瘤靶向性的厄洛替尼‑Cy7‑壳聚糖聚合物
Tang et al. Structure of a polysaccharide MDP2-1 from Melastoma dodecandrum Lour. and its anti-inflammatory effects
Shen et al. An antitumor fungal polysaccharide from Fomitopsis officinalis by activating immunity and inhibiting angiogenesis
Lin et al. An acidic heteropolysaccharide rich in galactose and arabinose derived from ginger: Structure and dynamics
CA2916749C (en) Sulfated polygulonic acid polysaccharide or pharmaceutical salt thereof, preparation method therefor and use thereof
CN103382229B (zh) 一种具有免疫调节作用的新型海胆黄多糖的制备方法及结构鉴定
Li et al. Anti-tumor and anti-metastasis of water-soluble sulfated β-glucan derivatives from Saccharomyces cerevisiae
NL2032675B1 (en) Inonotus obliquus dextran and preparation method and application thereof
CN107158410A (zh) 一种具有肿瘤靶向性的叶酸‑壳聚糖‑Cy7聚合物及其制备方法
CN105412011A (zh) 一种载体本身具有抗肿瘤和抗转移活性的两亲性胶束
CN110452312A (zh) 一种具有抗消化系统癌症作用的霍山石斛多糖
US20220265697A1 (en) ß-GLUCAN COMPOSITION AND USE THEREFOR
CN113388044B (zh) 一种蜗牛糖胺聚糖化合物、其药学上可接受的盐、制备方法及应用
HK1220984B (zh) 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途
Dai et al. Alleviation of DSS-induced colitis by Meconopsis polysaccharides correlated with reduced PI3K/AKT signaling and gut microbiome diversity
Wang et al. Elucidating the structures and antitumor activities of Pleione bulbocodioides polysaccharides
WO2021128253A1 (zh) 一种糖胺聚糖衍生物及其应用
Xie et al. A dual-target pectin-like polysaccharide LRP01B from Lamiophlomis rotata induces pancreatic cancer cell apoptosis in vitro and in vivo by causing mitochondrial dysfunction
CN117143261A (zh) Cpa荧光标记产物fcpa及其制备方法与应用
CN119529821A (zh) 一种利用h-聚集体增强巨噬细胞亚型特异性的多糖纳米探针及其制备方法和用途
CN120713860A (zh) 一种plga封装ge11肽偶联亲水型酞菁纳米光敏剂及其制备方法和应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190418

MKLA Lapsed

Effective date: 20220704